Search Results
Oct 30, 2025, 11:00 ET Clinical Late-Breaking Abstracts Announced for the Society for Immunotherapy of Cancer's 40th Anniversary Annual Meeting
(1342) First-in-human dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and initial efficacy of mRNA-LNP MT-302 in vivo CAR therapy in solid tumors Rasha Cosman, BSc (Med), MBBS, FRACP – St. Vincent's HospitalSession 104: Clinical
More news about: Society for Immunotherapy of Cancer (SITC)
Oct 29, 2025, 18:34 ET CREATE Medicines Unveils All-RNA T-Cell Engineering Platform: RetroT Enables Site-Specific, Durable CAR integration In Vivo
re-dose," said Robert Hofmeister, PhD, Chief Scientific Officer of CREATE Medicines. "When combined with our targeted LNP delivery and human-validated mRNA platform, RetroT provides a direct and scalable path to clinical proof of concept." By harnessing the natural mobility
More news about: CREATE Medicines, Inc.
Oct 29, 2025, 15:59 ET FDA Issues Formal Guideline Waiving Clinical Efficacy Studies for Biosimilars, Confirming Professor Niazi's 15-Year Campaign to Cut Biologic Drug Costs
recognized advisor to the FDA, EMA, MHRA, and U.S. Senate. With more than 100 books and scientific publications, his contributions span biosimilars, mRNA vaccines, protein engineering, and continuous manufacturing. His lifelong mission is to make advanced therapeutics accessible and affordable for all
More news about: Pharmaceutical Scientist, Inc.
Oct 29, 2025, 08:12 ET BioCina gibt Ernennung von Dr. Thomas Broudy zum Chief Executive Officer bekannt
BioCina gab kürzlich die Fusion seiner in Adelaide ansässigen Wirkstoffanlage, die sich auf die Produktion von mikrobiellen Proteinen, Plasmiden und mRNA/LNP konzentriert, mit seiner in Perth ansässigen großtechnischen Anlage für sterile Arzneimittel mit Abfüllanlagen für Ampullen, Fläschchen, Kartuschen
More news about: BioCina
Oct 28, 2025, 10:07 ET Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
simple structure and low molecular weight, holds strong potential for advanced applications like bispecific/multi-specific antibodies, ADCs, CAR-T, and mRNA therapies. However, conventional human VH domains struggle to maintain stability without VL pairing. Harbour BioMed's Harbour
More news about: Harbour BioMed
Oct 28, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Arcturus Therapeutics Holdings Inc. - ARCT
2025, Arcturus issued a press release "announc[ing] interim results from its ongoing Phase 2 clinical trial of ARCT-032, an investigational inhaled mRNA therapy for people with cystic fibrosis." The press release disclosed that patients in the trial had not shown a meaningful improvement in forced expiratory
More news about: Pomerantz LLP
Oct 28, 2025, 08:00 ET CREATE Medicines and Amsterdam University Medical Center Initiate First In Vivo CAR Therapy Trial in Frontline Setting for Solid Tumors
MT-302, a TROP2-targeting mRNA-LNP in vivo CAR therapy, is the first treatment of its kind to move into a frontline solid tumor trial Study builds on clinical experience from over 40 patients, one of the largest clinical datasets
More news about: CREATE Medicines, Inc.
Oct 28, 2025, 03:02 ET BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer
Immunology. BioCina recently announced the merger of its Adelaide-based drug substance facility, focused on microbial protein, plasmid, and mRNA/LNP production, and its Perth-based large scale commercial sterile drug product facility, with filling lines for ampoules, vials, cartridges and prefilled
More news about: BioCina
Oct 28, 2025, 03:02 ET BioCina Announces Appointment of Dr. Thomas Broudy as Chief Executive Officer
Immunology. BioCina recently announced the merger of its Adelaide-based drug substance facility, focused on microbial protein, plasmid, and mRNA/LNP production, and its Perth-based large scale commercial sterile drug product facility, with filling lines for ampoules, vials, cartridges and prefilled
More news about: BioCina
Oct 28, 2025, 02:50 ET Samsung Biologics reports third quarter 2025 financial results
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes,
More news about: Samsung Biologics
Oct 27, 2025, 08:30 ET Advancing Cell Therapy Development with Integrated Analytical and Process Strategies, Upcoming Webinar Hosted by Xtalks
In this free webinar, explore approaches to developing and implementing proliferation, AAV/mRNA potency, cell killing and flow cytometry assays in cell therapy development. Attendees will learn how analytical and process development (PD/AD) workflows can rapidly
More news about: Xtalks
Oct 27, 2025, 08:00 ET Pancreatic Cancer Clinical Trial Data for Diakonos Oncology's DOC1021 Cell-Based Immunotherapy to be Presented at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
patient-derived double-loaded dendritic cell therapy that uniquely combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient's dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens. The unique double-loading
More news about: Diakonos Oncology
Oct 26, 2025, 03:53 ET WuXi AppTec Achieves Strong Double-Digit Growth in Revenue and Profit for Q1-Q3 2025 Backlog for Continuing Operations Up 41.2% YoY Further Raises 2025 Full-year Guidance
licensing. New modality business continued to develop, while the Company maintained its leading position in areas including nucleic acids, conjugates, mRNA, multispecific antibodies and peptides. The Company continued to advance automation. DMPK successfully launched its proprietary
More news about: WuXi AppTec
Oct 24, 2025, 12:30 ET Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
marker among clinically validated and emerging ADC targets, after HER2 and HER3. Highest median PTK7 mRNA expression1 observed in endometrial (7.4), ovarian (7.2), head and neck (7.1), non-small cell lung cancer (NSCLC) (6.9) and breast
More news about: Whitehawk Therapeutics, Inc.
Oct 24, 2025, 08:00 ET Orna Therapeutics Announces Encore Presentation at the American College of Rheumatology Annual Meeting Supporting its in vivo CAR Therapy Approach in Autoimmune Diseases
therapeutics to unlock the potential of RNA medicine to treat diseases anywhere in the body. Orna's oRNA transcripts have advantages over traditional mRNA approaches, including simplified production, improved formulation into lipid nanoparticles, and superior protein expression. Its industry-leading LNP-based
More news about: Orna Therapeutics
Oct 23, 2025, 09:21 ET METiS BioTech announces China's First AI-Enabled Formulation Drug Candidate to Complete Phase III Clinical Trial
platform and three proprietary platform technologies, AiLNP – AI platform for nucleic acid delivery system design; AiRNA – AI platform for mRNA sequence optimization; and AiTEM – AI platform for small molecule formulation design. METiS' platforms
More news about: METiS TechBio
Oct 21, 2025, 08:23 ET Hoth Therapeutics Reports FDA Orphan Drug Designation and Strong Preclinical Data for HT-KIT in Rare c-KIT-Driven Cancers
significant tumor-volume reduction by Day 8 in systemic mastocytosis and GIST models. HT-KIT, a precision antisense oligonucleotide (ASO) targeting KIT mRNA, also completed GLP-validated bioanalytical methods supporting IND-enabling studies; Japan Patent No. 7677628 extends platform protection to 2039.
More news about: Hoth Therapeutics, Inc.
Oct 20, 2025, 07:43 ET Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
2nd panel: Gene Therapy and mRNA Therapeutics Explore how gene and mRNA therapies are translating promise into practice, tackling challenges in delivery, durability, and safety, and
More news about: GenScript Biotech Corporation
Oct 19, 2025, 10:49 ET iOncologi Secures Foundational U.S. Patent as Landmark Studies Link COVID19 mRNA Vaccines to Improved Survival with Cancer Immunotherapy
Congress in Berlin. The presentation, titled "SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade," reported that mRNA-based immune activation, achieved through SARS-CoV-2 mRNA vaccination, correlated with significantly improved overall survival among checkpoint-treated
More news about: iOncologi, Inc.
Oct 15, 2025, 10:30 ET Life Science Logistics Market is expected to generate a revenue of USD 236.28 Billion by 2032, Globally, at 8% CAGR: Verified Market Research®
the logistics sector must evolve to ensure secure handling and distribution. The rise of mRNA vaccines, cell and gene therapies, and specialty drugs has amplified the need for precision cold chain management. Logistics
More news about: Verified Market Research
Oct 15, 2025, 08:00 ET SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
against future outbreaks." Beyond GBP511, SK bioscience is advancing multiple pandemic-preparedness programs. These include an mRNA-based Japanese encephalitis vaccine currently in Phase 1/2 global studies with CEPI, and a government-backed avian influenza vaccine program launched
More news about: SK bioscience
Oct 15, 2025, 03:20 ET 워터스, '전하 검출 질량 분석 기술' 출시, 차세대 바이오 치료제 개발 가속
Detection Mass Spectrometer, 이하 'CDMS')'를공개했다. 세포및유전자치료제, mRNA, 복합단백질치료제의급속한성장으로과학자들은점점더크고
More news about: Waters Corporation
Oct 14, 2025, 20:00 ET Nona Biosciences Appoints Dr. Di Hong as Chief Executive Officer to Drive Technology Innovation and Strategic Growth
antibodies as a plug-and-play system, including bispecific antibodies, multi-specific antibodies, CAR-T therapies, antibody-drug conjugates (ADCs), mRNA-based therapeutics, and more. By integrating Harbour Mice®, single-B cell screening technology, NonaCarFxTM
More news about: Nona Biosciences
Oct 14, 2025, 08:30 ET Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025
Impact of Androgen Deprivation Therapy (ADT) on KLK2 mRNA Expression and Immunologic Correlates Across Prostate Cancer Disease States (Presentation Number: 2437P)Saturday, Oct 18, 2025
More news about: Caris Life Sciences
Oct 14, 2025, 02:50 ET Waters、次世代バイオ治療薬の開発を加速するための電荷検出質量分析技術を発表
Waters Xevo Charge Detection Mass Spectrometer（電荷検出質量分析計、以下CDMS）を発表しました。細胞・遺伝子治療、mRNA、および複雑なタンパク質治療薬の急速な発展に伴い、研究者はますます巨大かつ不均一な医薬品モダリティの解析において重大な課題に直面しています。しかし、既存の分析ツールは分解能、感度、そしてコンプライアンス対応の点で限界がありました。Xevo CDMSシステムは、最大150メガダルトン（MDa）を超える分子を対象に、粒子単位で直接質量を測定することで、これらの課題を解決します。これにより、これまで解析が困難であったタンパク質複合体、核酸、脂質ナノ粒子、ウイルスベクターなどの詳細な分析が可能になります。
More news about: Waters Corporation